COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Medicare & Medicaid Services will allow health insurers to offer premium reductions for individuals with 2020 coverage in the individual and small group markets when consistent with state law, the agency announced.
The ºÚÁÏÕýÄÜÁ¿ Association (AHA) urges the Centers for Medicare & Medicaid Services (CMS) to allow periodic interim payment (PIP) hospitals to carry out their accelerated payment repayment at cost settlement, as was initially communicated by the agency. We also request that the agency…
The Department of Health and Human Services updated its guidance and FAQs regarding the agency’s request for daily COVID-19-related hospital data reporting.
The Centers for Disease Control and Prevention Aug. 3 at 3 p.m. ET will hold a webinar with updates on the COVID-19 response, including new resources for businesses and other private-sector organizations.
A study released by the Centers for Disease Control and Prevention demonstrates that SARS-CoV-2 spreads efficiently in youth-centric settings, resulting in high attack rates among persons in all age groups.
The Food and Drug Administration updated its FAQs on the emergency use authorization of remdesivir for use on certain hospitalized COVID-19 patients. The document includes information on the changes to Gilead’s fact sheets for health care providers and patient caregivers.
The Centers for Medicare & Medicaid Services added 12 new ICD-10 procedure codes to identify new therapies for COVID-19.
The Centers for Disease Control and Prevention Aug. 4 at 2 p.m. ET will host a Clinician Outreach and Communication Activity webinar on telehealth’s benefits and challenges, based on lessons learned during the COVID-19 pandemic.
The Food and Drug Administration released a new template to help commercial developers submit emergency use authorization requests for COVID-19 diagnostic tests that can be performed in non-laboratory settings and available by prescription or over-the-counter.
The Centers for Medicare & Medicaid Services updated its COVID-19 FAQs to address emerging questions regarding Medicare fee-for-service billing.